 | • レポートコード：MRC2-11QY11470 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は先天性心疾患のグローバル市場について調査・分析したレポートです。種類別（医薬品、埋込型心臓装置、カテーテル処置、開心術、心臓移植）市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別先天性心疾患の競争状況、市場シェア ・世界の先天性心疾患市場：種類別市場規模 2015年-2020年（医薬品、埋込型心臓装置、カテーテル処置、開心術、心臓移植） ・世界の先天性心疾患市場：種類別市場規模予測 2021年-2026年（医薬品、埋込型心臓装置、カテーテル処置、開心術、心臓移植） ・世界の先天性心疾患市場：用途別市場規模 2015年-2020年（病院・クリニック、診断センター） ・世界の先天性心疾患市場：用途別市場規模予測 2021年-2026年（病院・クリニック、診断センター） ・北米の先天性心疾患市場分析：米国、カナダ ・ヨーロッパの先天性心疾患市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの先天性心疾患市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の先天性心疾患市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの先天性心疾患市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abbott Diagnostics、Array BioPharma、AstraZeneca、Becton Dickinson、BG Medicine、Bio-Rad、Boston Scientific、Covance、Critical Diagnostics、Roche、GSK、Janssen Pharmaceuticals、Medtronic、Merck、Mylan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
A congenital heart disease is a problem in the structure of the heart that is present at birth.
The factors driving the growth of the global congenital heart disease market are rising prevalence of congenital heart disease and rise in adoption of minimally invasive procedures. Further, large number of dominating market players, growing demand for catheterization and application of cardiac biomarkers in congenital heart disease treatment are also considered as a major factor for driving the growth of the global congenital heart disease market during forecast period.
Market Analysis and Insights: Global Congenital Heart Disease Market
The global Congenital Heart Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Congenital Heart Disease Scope and Market Size
Congenital Heart Disease market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Congenital Heart Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Abbott Diagnostics
Array BioPharma
AstraZeneca
Becton Dickinson
BG Medicine
Bio-Rad
Boston Scientific
Covance
Critical Diagnostics
Roche
GSK
Janssen Pharmaceuticals
Medtronic
Merck
Mylan
Market segment by Type, the product can be split into
Medications
Implantable heart devices
Catheter procedures
Open-heart surgery
Heart transplant
Market segment by Application, split into
Hospitals and clinics
Diagnostic centres
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Congenital Heart Disease Revenue
1.4 Market by Type
1.4.1 Global Congenital Heart Disease Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medications
1.4.3 Implantable heart devices
1.4.4 Catheter procedures
1.4.5 Open-heart surgery
1.4.6 Heart transplant
1.5 Market by Application
1.5.1 Global Congenital Heart Disease Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and clinics
1.5.3 Diagnostic centres
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Congenital Heart Disease Market Perspective (2015-2026)
2.2 Global Congenital Heart Disease Growth Trends by Regions
2.2.1 Congenital Heart Disease Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Congenital Heart Disease Historic Market Share by Regions (2015-2020)
2.2.3 Congenital Heart Disease Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Congenital Heart Disease Market Growth Strategy
2.3.6 Primary Interviews with Key Congenital Heart Disease Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Disease Players by Market Size
3.1.1 Global Top Congenital Heart Disease Players by Revenue (2015-2020)
3.1.2 Global Congenital Heart Disease Revenue Market Share by Players (2015-2020)
3.1.3 Global Congenital Heart Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Congenital Heart Disease Market Concentration Ratio
3.2.1 Global Congenital Heart Disease Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Congenital Heart Disease Revenue in 2019
3.3 Congenital Heart Disease Key Players Head office and Area Served
3.4 Key Players Congenital Heart Disease Product Solution and Service
3.5 Date of Enter into Congenital Heart Disease Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Congenital Heart Disease Historic Market Size by Type (2015-2020)
4.2 Global Congenital Heart Disease Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Congenital Heart Disease Market Size by Application (2015-2020)
5.2 Global Congenital Heart Disease Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Congenital Heart Disease Market Size (2015-2020)
6.2 Congenital Heart Disease Key Players in North America (2019-2020)
6.3 North America Congenital Heart Disease Market Size by Type (2015-2020)
6.4 North America Congenital Heart Disease Market Size by Application (2015-2020)
7 Europe
7.1 Europe Congenital Heart Disease Market Size (2015-2020)
7.2 Congenital Heart Disease Key Players in Europe (2019-2020)
7.3 Europe Congenital Heart Disease Market Size by Type (2015-2020)
7.4 Europe Congenital Heart Disease Market Size by Application (2015-2020)
8 China
8.1 China Congenital Heart Disease Market Size (2015-2020)
8.2 Congenital Heart Disease Key Players in China (2019-2020)
8.3 China Congenital Heart Disease Market Size by Type (2015-2020)
8.4 China Congenital Heart Disease Market Size by Application (2015-2020)
9 Japan
9.1 Japan Congenital Heart Disease Market Size (2015-2020)
9.2 Congenital Heart Disease Key Players in Japan (2019-2020)
9.3 Japan Congenital Heart Disease Market Size by Type (2015-2020)
9.4 Japan Congenital Heart Disease Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Congenital Heart Disease Market Size (2015-2020)
10.2 Congenital Heart Disease Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Congenital Heart Disease Market Size by Type (2015-2020)
10.4 Southeast Asia Congenital Heart Disease Market Size by Application (2015-2020)
11 India
11.1 India Congenital Heart Disease Market Size (2015-2020)
11.2 Congenital Heart Disease Key Players in India (2019-2020)
11.3 India Congenital Heart Disease Market Size by Type (2015-2020)
11.4 India Congenital Heart Disease Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Congenital Heart Disease Market Size (2015-2020)
12.2 Congenital Heart Disease Key Players in Central & South America (2019-2020)
12.3 Central & South America Congenital Heart Disease Market Size by Type (2015-2020)
12.4 Central & South America Congenital Heart Disease Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Abbott Diagnostics
13.1.1 Abbott Diagnostics Company Details
13.1.2 Abbott Diagnostics Business Overview
13.1.3 Abbott Diagnostics Congenital Heart Disease Introduction
13.1.4 Abbott Diagnostics Revenue in Congenital Heart Disease Business (2015-2020))
13.1.5 Abbott Diagnostics Recent Development
13.2 Array BioPharma
13.2.1 Array BioPharma Company Details
13.2.2 Array BioPharma Business Overview
13.2.3 Array BioPharma Congenital Heart Disease Introduction
13.2.4 Array BioPharma Revenue in Congenital Heart Disease Business (2015-2020)
13.2.5 Array BioPharma Recent Development
13.3 AstraZeneca
13.3.1 AstraZeneca Company Details
13.3.2 AstraZeneca Business Overview
13.3.3 AstraZeneca Congenital Heart Disease Introduction
13.3.4 AstraZeneca Revenue in Congenital Heart Disease Business (2015-2020)
13.3.5 AstraZeneca Recent Development
13.4 Becton Dickinson
13.4.1 Becton Dickinson Company Details
13.4.2 Becton Dickinson Business Overview
13.4.3 Becton Dickinson Congenital Heart Disease Introduction
13.4.4 Becton Dickinson Revenue in Congenital Heart Disease Business (2015-2020)
13.4.5 Becton Dickinson Recent Development
13.5 BG Medicine
13.5.1 BG Medicine Company Details
13.5.2 BG Medicine Business Overview
13.5.3 BG Medicine Congenital Heart Disease Introduction
13.5.4 BG Medicine Revenue in Congenital Heart Disease Business (2015-2020)
13.5.5 BG Medicine Recent Development
13.6 Bio-Rad
13.6.1 Bio-Rad Company Details
13.6.2 Bio-Rad Business Overview
13.6.3 Bio-Rad Congenital Heart Disease Introduction
13.6.4 Bio-Rad Revenue in Congenital Heart Disease Business (2015-2020)
13.6.5 Bio-Rad Recent Development
13.7 Boston Scientific
13.7.1 Boston Scientific Company Details
13.7.2 Boston Scientific Business Overview
13.7.3 Boston Scientific Congenital Heart Disease Introduction
13.7.4 Boston Scientific Revenue in Congenital Heart Disease Business (2015-2020)
13.7.5 Boston Scientific Recent Development
13.8 Covance
13.8.1 Covance Company Details
13.8.2 Covance Business Overview
13.8.3 Covance Congenital Heart Disease Introduction
13.8.4 Covance Revenue in Congenital Heart Disease Business (2015-2020)
13.8.5 Covance Recent Development
13.9 Critical Diagnostics
13.9.1 Critical Diagnostics Company Details
13.9.2 Critical Diagnostics Business Overview
13.9.3 Critical Diagnostics Congenital Heart Disease Introduction
13.9.4 Critical Diagnostics Revenue in Congenital Heart Disease Business (2015-2020)
13.9.5 Critical Diagnostics Recent Development
13.10 Roche
13.10.1 Roche Company Details
13.10.2 Roche Business Overview
13.10.3 Roche Congenital Heart Disease Introduction
13.10.4 Roche Revenue in Congenital Heart Disease Business (2015-2020)
13.10.5 Roche Recent Development
13.11 GSK
10.11.1 GSK Company Details
10.11.2 GSK Business Overview
10.11.3 GSK Congenital Heart Disease Introduction
10.11.4 GSK Revenue in Congenital Heart Disease Business (2015-2020)
10.11.5 GSK Recent Development
13.12 Janssen Pharmaceuticals
10.12.1 Janssen Pharmaceuticals Company Details
10.12.2 Janssen Pharmaceuticals Business Overview
10.12.3 Janssen Pharmaceuticals Congenital Heart Disease Introduction
10.12.4 Janssen Pharmaceuticals Revenue in Congenital Heart Disease Business (2015-2020)
10.12.5 Janssen Pharmaceuticals Recent Development
13.13 Medtronic
10.13.1 Medtronic Company Details
10.13.2 Medtronic Business Overview
10.13.3 Medtronic Congenital Heart Disease Introduction
10.13.4 Medtronic Revenue in Congenital Heart Disease Business (2015-2020)
10.13.5 Medtronic Recent Development
13.14 Merck
10.14.1 Merck Company Details
10.14.2 Merck Business Overview
10.14.3 Merck Congenital Heart Disease Introduction
10.14.4 Merck Revenue in Congenital Heart Disease Business (2015-2020)
10.14.5 Merck Recent Development
13.15 Mylan
10.15.1 Mylan Company Details
10.15.2 Mylan Business Overview
10.15.3 Mylan Congenital Heart Disease Introduction
10.15.4 Mylan Revenue in Congenital Heart Disease Business (2015-2020)
10.15.5 Mylan Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Congenital Heart Disease Key Market Segments
Table 2. Key Players Covered: Ranking by Congenital Heart Disease Revenue
Table 3. Ranking of Global Top Congenital Heart Disease Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Congenital Heart Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Medications
Table 6. Key Players of Implantable heart devices
Table 7. Key Players of Catheter procedures
Table 8. Key Players of Open-heart surgery
Table 9. Key Players of Heart transplant
Table 10. Global Congenital Heart Disease Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Congenital Heart Disease Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Congenital Heart Disease Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Congenital Heart Disease Market Share by Regions (2015-2020)
Table 14. Global Congenital Heart Disease Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Congenital Heart Disease Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Congenital Heart Disease Market Growth Strategy
Table 20. Main Points Interviewed from Key Congenital Heart Disease Players
Table 21. Global Congenital Heart Disease Revenue by Players (2015-2020) (Million US$)
Table 22. Global Congenital Heart Disease Market Share by Players (2015-2020)
Table 23. Global Top Congenital Heart Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Heart Disease as of 2019)
Table 24. Global Congenital Heart Disease by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Congenital Heart Disease Product Solution and Service
Table 27. Date of Enter into Congenital Heart Disease Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 30. Global Congenital Heart Disease Market Size Share by Type (2015-2020)
Table 31. Global Congenital Heart Disease Revenue Market Share by Type (2021-2026)
Table 32. Global Congenital Heart Disease Market Size Share by Application (2015-2020)
Table 33. Global Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 34. Global Congenital Heart Disease Market Size Share by Application (2021-2026)
Table 35. North America Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Congenital Heart Disease Market Share (2019-2020)
Table 37. North America Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 38. North America Congenital Heart Disease Market Share by Type (2015-2020)
Table 39. North America Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 40. North America Congenital Heart Disease Market Share by Application (2015-2020)
Table 41. Europe Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Congenital Heart Disease Market Share (2019-2020)
Table 43. Europe Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Congenital Heart Disease Market Share by Type (2015-2020)
Table 45. Europe Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Congenital Heart Disease Market Share by Application (2015-2020)
Table 47. China Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 48. China Key Players Congenital Heart Disease Market Share (2019-2020)
Table 49. China Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 50. China Congenital Heart Disease Market Share by Type (2015-2020)
Table 51. China Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 52. China Congenital Heart Disease Market Share by Application (2015-2020)
Table 53. Japan Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Congenital Heart Disease Market Share (2019-2020)
Table 55. Japan Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Congenital Heart Disease Market Share by Type (2015-2020)
Table 57. Japan Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Congenital Heart Disease Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Congenital Heart Disease Market Share (2019-2020)
Table 61. Southeast Asia Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Congenital Heart Disease Market Share by Type (2015-2020)
Table 63. Southeast Asia Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Congenital Heart Disease Market Share by Application (2015-2020)
Table 65. India Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 66. India Key Players Congenital Heart Disease Market Share (2019-2020)
Table 67. India Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 68. India Congenital Heart Disease Market Share by Type (2015-2020)
Table 69. India Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 70. India Congenital Heart Disease Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Congenital Heart Disease Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Congenital Heart Disease Market Share (2019-2020)
Table 73. Central & South America Congenital Heart Disease Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Congenital Heart Disease Market Share by Type (2015-2020)
Table 75. Central & South America Congenital Heart Disease Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Congenital Heart Disease Market Share by Application (2015-2020)
Table 77. Abbott Diagnostics Company Details
Table 78. Abbott Diagnostics Business Overview
Table 79. Abbott Diagnostics Product
Table 80. Abbott Diagnostics Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 81. Abbott Diagnostics Recent Development
Table 82. Array BioPharma Company Details
Table 83. Array BioPharma Business Overview
Table 84. Array BioPharma Product
Table 85. Array BioPharma Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 86. Array BioPharma Recent Development
Table 87. AstraZeneca Company Details
Table 88. AstraZeneca Business Overview
Table 89. AstraZeneca Product
Table 90. AstraZeneca Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 91. AstraZeneca Recent Development
Table 92. Becton Dickinson Company Details
Table 93. Becton Dickinson Business Overview
Table 94. Becton Dickinson Product
Table 95. Becton Dickinson Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 96. Becton Dickinson Recent Development
Table 97. BG Medicine Company Details
Table 98. BG Medicine Business Overview
Table 99. BG Medicine Product
Table 100. BG Medicine Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 101. BG Medicine Recent Development
Table 102. Bio-Rad Company Details
Table 103. Bio-Rad Business Overview
Table 104. Bio-Rad Product
Table 105. Bio-Rad Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 106. Bio-Rad Recent Development
Table 107. Boston Scientific Company Details
Table 108. Boston Scientific Business Overview
Table 109. Boston Scientific Product
Table 110. Boston Scientific Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 111. Boston Scientific Recent Development
Table 112. Covance Business Overview
Table 113. Covance Product
Table 114. Covance Company Details
Table 115. Covance Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 116. Covance Recent Development
Table 117. Critical Diagnostics Company Details
Table 118. Critical Diagnostics Business Overview
Table 119. Critical Diagnostics Product
Table 120. Critical Diagnostics Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 121. Critical Diagnostics Recent Development
Table 122. Roche Company Details
Table 123. Roche Business Overview
Table 124. Roche Product
Table 125. Roche Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 126. Roche Recent Development
Table 127. GSK Company Details
Table 128. GSK Business Overview
Table 129. GSK Product
Table 130. GSK Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 131. GSK Recent Development
Table 132. Janssen Pharmaceuticals Company Details
Table 133. Janssen Pharmaceuticals Business Overview
Table 134. Janssen Pharmaceuticals Product
Table 135. Janssen Pharmaceuticals Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 136. Janssen Pharmaceuticals Recent Development
Table 137. Medtronic Company Details
Table 138. Medtronic Business Overview
Table 139. Medtronic Product
Table 140. Medtronic Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 141. Medtronic Recent Development
Table 142. Merck Company Details
Table 143. Merck Business Overview
Table 144. Merck Product
Table 145. Merck Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 146. Merck Recent Development
Table 147. Mylan Company Details
Table 148. Mylan Business Overview
Table 149. Mylan Product
Table 150. Mylan Revenue in Congenital Heart Disease Business (2015-2020) (Million US$)
Table 151. Mylan Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Congenital Heart Disease Market Share by Type: 2020 VS 2026
Figure 2. Medications Features
Figure 3. Implantable heart devices Features
Figure 4. Catheter procedures Features
Figure 5. Open-heart surgery Features
Figure 6. Heart transplant Features
Figure 7. Global Congenital Heart Disease Market Share by Application: 2020 VS 2026
Figure 8. Hospitals and clinics Case Studies
Figure 9. Diagnostic centres Case Studies
Figure 10. Congenital Heart Disease Report Years Considered
Figure 11. Global Congenital Heart Disease Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Congenital Heart Disease Market Share by Regions: 2020 VS 2026
Figure 13. Global Congenital Heart Disease Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Congenital Heart Disease Market Share by Players in 2019
Figure 16. Global Top Congenital Heart Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Heart Disease as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Congenital Heart Disease Revenue in 2019
Figure 18. North America Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Congenital Heart Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
炎症性心疾患の世界市場（～2026年） Inflammatory heart disease is mainly caused by various infectious agents which includes viruses, bacteria, fungi and parasites. These infectious agents came into contact with human body via various toxic materials from the environment. Changing lifestyle resulting in higher prevalence of viral and f…- リウマチ性心臓病の世界市場（～2026年） Rheumatic heart disease is a complication ofrheumatic fever in which the heart valves are damaged. Increasing environmental pollution resulting in higher prevalence of viral and fungal infection is one of the major factor motivating the growth of this market. In addition, increasing healthcare expen…
- 虚血性心疾患（IHD）薬の世界市場（～2026年） Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may tr…
- 心臓弁修復・交換の世界市場（～2026年） Heart valve is a thin flap of tissue, which ensures the unidirectional flow of blood throughout the cardiac cycle. Tricuspid valve, mitral valve, aortic valve, and pulmonary valve are the primary four valves in the heart. Valvular stenosis, atresia, valvular inadequacy or regurgitation, and prolapse…
- 心臓健康製品の世界市場（～2026年） Heart Health Products are defined as supplements that help in treating the heart health conditions. Heart health products can be fortified food products, functional food or dietary supplements extracted from the natural resources. The products are designed in order to keep the cholesterol level low …